Laigo Bio, a Utrecht-based BioTech firm focapplyd on protein degradation for tarreceiveed therapies, has concluded the second close of its Seed funding round, raising an extra €5.5 million, bringing the total amount raised to €17 million.
The €5.5 million raised includes additional funding of €4 million secured from new co-lead investor Biovance Capital and €1.5 million from existing co-lead Kurma Partners. With this funding, Dr João Incio, General Partner at Biovance Capital, will join Laigo’s board of directors. Laigo Bio completed the initial close of its Seed financing round at €11.5 million in December 2025.
“The second close of our seed financing round further validates the potential of our SureTACs platform and its ability to identify first-in-class dual tarreceiveed therapies to redefine the treatment of cancer and autoimmune diseases. The additional investment and support from new co-lead investor Biovance Capital, alongside further funding from our existing co-lead investor Kurma Partners, will accelerate our oncology programs towards the clinic and enhance our discovery efforts in auto-immunity and immunology. We welcome Dr João Incio to the Board of Directors,” stated Dr Matthew Baker, Chief Executive Officer of Laigo Bio.
Laigo Bio was founded by the Oncode Institute, toreceiveher with the Oncode Bridge Fund, and Argobio Studio, a French BioTech startup studio launched by Kurma Partners, BPI France and Angelini Ventures, key players in financing innovation in healthcare.
Argobio Studio was launched in 2021 with €50 million of committed capital to create and develop innovative BioTech spinouts, focapplying on specific therapeutic areas such as rare diseases, neurological disorders, oncology, and immunology.
Laigo Bio applyd E3 ligase-induced internalisation and selective degradation of membrane-bound tarreceives involved in autoimmune and inflammatory diseases. The company has devised a novel technology (SureTACs) that facilitates the precise removal of proteins located on any cell surface.
SureTACs, developed in collaboration with Prof Madelon Maurice’s laboratory at the UMC Utrecht and the Oncode Institute, are proprietary therapeutic candidates for the tarreceiveed degradation of membrane proteins that have been validated as disease drivers but have previously eluded drug discovery and were long considered “undruggable”.
SureTACs are bispecific antibody molecules that induce degradation by bringing the cell surface tarreceive protein into close proximity with a surface E3 ligase enzyme, resulting in highly selective and deep inhibition of disease pathways in affected tissues.
“Its proprietary Surface Removal Tarreceiveing Chimeras (SureTACs) platform generates bispecific antibodies that pair the optimal E3 ligase with a disease-caapplying tarreceive protein to stimulate its ubiquitination and lysosomal degradation with a high degree of specificity. Laigo’s platform allows the development of first-in-class, dual-tarreceiveed therapies that eliminate disease-driving membrane tarreceives,” the company explained.
Laigo notes that degrading the tarreceive protein results in more effective inhibition of disease pathways compared to conventional therapeutics, while protecting healthy tissue and reducing side effects.
With the fresh capital, the company plans to accelerate the development of its SureTACs oncology programmes towards the clinic, as well as advance its three candidate programmes for selected autoimmune and immunology indications and graft rejection.
Laigo is supported by a syndicate of prominent international investors, such as Kurma Partners, Biovance Capital, Curie Capital, Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region, and Cancer Research Horizons.
Leave a Reply